Scientific Online Resource System

Heart - Lung (Varna)

Cardiovascular architectural changes in patients with chronic kidney disease with secondary hyperparathyroidism

Svetla Staykova

Abstract

Cardiovascular diseases (CVD) are common in patients with chronic renal failure and are the leading cause of morbidity and mortality in patients on dialysis treatment. The CVD score is higher in patients with chronic kidney disease (CKD) (5th stage), where mortality reaches almost 100 times that of the general population.
Approximately 80% of the patients on dialysis have left ventricular hypertrophy (LVH) even before extracorporeal treatment is started. LVH is an adaptive process that develops as a result of increased heart rate due to continuous and excessively increased pressure (increased overload) and bulk load (increased overload). Deepening of anemic syndrome, uncontrolled arterial hypertension, proven diabetes mellitus and secondary hyperparathyroidism are widespread in patients with CKD.
Initially, arterial calcification was described as passive deposition of amorphous material under conditions of hyperphosphatemia and transient increases in calcium levels recorded during CKD.

Keywords

cardiovascular risk; CKD; calcifications; hyperphosphatemia

Full Text


References

Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, et al. Inflammation, Malnutrition, and Cardiac Disease as Predictors of mortality in Hemodialysis Patients. J Am Soc Nephrol. 2002;13 Suppl 1:S28-36.

Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome:Guyton revisited. Eur Heart J. 2005;26(1):11-7.

Herzog CA, Mangrum JM, Passman R. Non- coronary heart disease in dialysis patients: Sudden Cardiac Death and Dialysis Patients. Seminars in Dialysis. 2008;21(4):300-7. doi: 10.1111/j.1525- 139X.2008.00455.x.

Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Ins. 2001, 62:245- 252.

Calabrese D. Management of cardiovascular disease in chronic kidney disease:Implications for managed care. Am J Manag Care. 2011;17(Suppl. 15):S412- 8.

Foley RN, Collins AJ. A novel model of cardiovascular risk based of kidney function. Am J Nephrol. 2011;34(6):505-11. doi: 10.1159/000332997.

Goldberg A, Hammerman H, Petcherski S, Zdoro-

vyak A, Yalonetsky S, Kapeliovich M, et al. In- hospital and 1-year mortality of patients who de- velop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J. 2005;150(2):330-7. doi: 10.1016/j.ahj.2004.09.055.

Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease : a systematic review and meta- analysis. Clin J Am Soc Nephrol. 2011;6(10):2364- 73. doi: 10.2215/CJN.02180311.

Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al. The prognostic importance of different of worsening renal function in congestive heart failure. J Card Fail. 2008;8(3):136-41.

Hassan NA, D`Orsi ET, D`Orsi CJ, O`Neill WC. The risk for medial arterial calcification in CDK. Clin J Am Soc Nephrol. 2012 Feb;7(2):275-9. doi: 10.2215/CJN.06490711.

Resić H, Prnjavorac B, Masnić F, Ajanović S, Kukavica N, Bećiragić A. Evaluation and treatment of cardiovascular diseases in patients on hemodialysis - single center experience. Med Glas (Zenica). 2011;8(1):158-62.

Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol. 2009;53(8):639- 47. doi: 10.1016/j.jacc.2008.

K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. National Kidney Foundation. Am J Kidney Dis . 2005;45(4), Suppl. 3:1-153.

Jager KJ, Lindholm B, Goldsmith D, Fliser D, Wiecek A, Suleymanlar G, et al. Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link? ISN. Kidney Int Suppl (2011). 2011;1(1):21-3. doi: 10.1038/kisup.2011.7.

London G, Coyne D, Hruska K, Malluche HH, Martin KJ. The new kidney disease : improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol. 2010 Dec;74(6):423-32.

Sonician M, Parissis JT. Cardiovascular disease and hemodialysis : novel strategies for diagnosis, prevention and treatment. Hellenic J Cardiol. 2003,44:206-17.

McCullough PA, Agrawal V, Danielewicz E, Abela GS. Accelerated atherosclerotic calcification and Monckeberg`s sclerosis: a continuum of advanced

vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1585-98. doi: 10.2215/ CJN.01930408.

Mittalhenkle A, Stehman-Breen CO, Shlipak MG, Fried LF, Katz R, Young BA, et al. Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. Clin J Am Soc Nephrol. 2008; 3(2):450-6. doi: 10.2215/ CJN.02610607.

Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, et al. Cardiorenal interactions : insights from the ESCAPE trial. J Am Coll Cardiol. 2008, 51(13):1268-74. doi: 10.1016/j. jacc.2007.08.072.

Palazzuoli A, Gallotta M, Iovine F, Nuti R, Silverberg DS. Anemia in heart failure : a common interaction with renal insufficiency called the cardio-renal anaemia syndrome. Int J Clin Pract. 2008;62(2):281- 6. doi: 10.1111/j.1742-1241.2007.01650.x

Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre

P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta - analysis. Clin J Am Soc Nephrol. 2009;4(4):755-62. doi: 10.2215/CJN.02730608.

Agarwal R, Debella YT, Giduma HD, Light RP. Long

- term retinal, renal and Cardiovascular outcomes in diabetic chronic kidney disease without proteinuria. Nephrol Dial Transplant. 2012;27(1):310-7. doi: 10.1093/ndt/gfr320.

Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med, 2008;34(5):957-62. doi: 10.1007/s00134-008-1017- 8.

Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol. 2009;5:287-96. doi:10.1038/nrne- ph.2009.42.

Veila S, Silva V, et al. Cardiovascular disease in patients with ESRD on hemodialysis in developing country. Saudy J Kidney Dis Transp. 2012;23(2):262-6.

Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788-93. doi: 10.1681/ASN.2004040275.




DOI: http://dx.doi.org/10.14748/hl.v18i3-4.4194

Refbacks

Font Size


|